CAMBRIDGE, Mass., Nov. 22 /PRNewswire/ -- Xanthus Life Sciences, Inc., a privately-held oncology drug development company, today announced that Richard T. Dean, Ph.D., President and CEO of Xanthus, will present a company overview and update at the Lazard Capital Markets Life Sciences Conference. The presentation is scheduled for Wednesday, November 30, 2005 at 3:00 pm at The New York Palace Hotel. A live audio webcast of the presentation will be available on the Company’s website located at http://www.xanthus.com. A replay of the presentation will be posted on the Xanthus website approximately thirty minutes after the event.
About Xanthus Life Sciences, Inc.
Xanthus Life Sciences, Inc. is developing a portfolio of novel, clinical- stage, small-molecule oncology candidates through a management team whose accomplished track record encompasses all aspects of drug development, from discovery through regulatory approval and commercialization. The Company is applying its expertise both to advance its current pipeline and expand it into indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional facility in Montreal, Quebec. More information is available at http://www.xanthus.com.
Contacts: Kari Watson, MacDougall Biomedical Communications, Inc. -- kwatson@macbiocom.com or (508) 647-0209 John A. McCarthy, Jr., Senior Vice President and Chief Financial Officer, Xanthus Life Sciences, Inc. -- (617) 225-0522 x125
Xanthus Life Sciences, Inc.
CONTACT: Kari Watson of MacDougall Biomedical Communications, Inc.,+1-508-647-0209, kwatson@macbiocom.com; or John A. McCarthy, Jr., SeniorVice President and Chief Financial Officer of Xanthus Life Sciences, Inc.,+1-617-225-0522 ext. 125
Web site: http://www.xanthus.com/
